Please assess the completion status of the following clinical trial:

Trial Title: Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: Between 20 and 79 years (at the time of giving informed consent).~* Sex: Either sex.~* Admission status: Outpatients.~* Patients requiring treatment for hypertension according to the JSH 2004 hypertension therapy guidelines before beginning this study~* Patients who have not used any calcium antagonists for at least 4 weeks before the beginning of this study.~* Patients who are scheduled to undergo elective PCI.~Exclusion Criteria:~* Patients with acute coronary syndrome (ACS).~* Patients who have experienced Q-wave myocardial infarction within 4 weeks before beginning this study.~* Patients with renal dysfunction (serum creatinine \>2.0 mg/dL).~* Patients in whom PCI is unsuccessful.~* Patients with cardiogenic shock.~* Patients with moderate or severe congestive heart failure.~* Patients with 50% or more stenosis of the main trunk of the left coronary artery.~* Patients with other problems whom the investigator considers unsuitable for this study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Amlodipine
- 2 (Type: ACTIVE_COMPARATOR): Azelnidipine

Based on this trial design, predict the completion outcome and termination type (if applicable).